Deficient dopamine D 2 receptor function causes renal inflammation independently of high blood pressure

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Zhang, Yanrong ^a   Cuevas, Santiago ^a   Asico, Laureano D ^a   Escano, Crisanto ^a   Yang, Yu ^a   Pascua, Annabelle M ^a   Wang, Xiaoyan ^a   Jones, John E ^a   Grandy, David ^b   Eisner, Gilbert ^c   Jose, Pedro A ^a   Armando, Ines ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; APOCYNIN; COMPLEMENTARY DNA; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOPAMINE 2 RECEPTOR GENE; DOWN REGULATION; GENE; GENE DELETION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE SILENCING; HISTOCHEMISTRY; HYPERTENSION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; MOUSE; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; URINALYSIS; WILD TYPE; ANIMAL; C57BL MOUSE; GENETICS; INFLAMMATION; KIDNEY DISEASE; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; DOWN-REGULATION; GENE EXPRESSION PROFILING; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY DISEASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, DOPAMINE D2;

EID: 84862255416     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038745     Document Type: Article

References (54)

1. Jose PA, Soares-da-Silva P, Eisner GM, Felder RA, (2010) Dopamine and G protein-coupled receptor kinase 4 in the kidney: Role in blood pressure regulation. Biochim Biophys Acta 802: 1259-1267.
2. Zeng C, Armando I, Luo Y, Eisner GM, Felder RA, et al. (2008) Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice. Am J Physiol Heart Circ Physiol 294: H551-H569.
3. Li XX, Bek M, Asico LD, Yang Z, Grandy DK, et al. (2001) Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type-2 knockout mice. Hypertension 38: 303-308.
4. Armando I, Wang X, Villar VA, Jones JE, Asico LD, et al. (2007) Reactive oxygen species-dependent hypertension in dopamine D2 receptor-deficient mice. Hypertension 49: 672-678.
5. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, et al. (2011) Inflammation, immunity, and hypertension. Hypertension 57: 132-140.
6. Segerer S, Schlöndorff D, (2007) Role of Chemokines for the Localization of Leukocyte Subsets in the Kidney. Semin Nephrol 27: 260-274.
7. Wang Y, Tay YC, Harris DC, (2004) Proximal tubule cells stimulated by lipopolysaccharide inhibit macrophage activation. Kidney Int 66: 655-662.
8. Bendele AM, Spaethe SM, Benslay DN, Bryant HU, (1991) Anti-inflammatory activity of pergolide, a dopamine receptor agonist. J Pharmacol Exp Ther 259: 169-175.
9. Ghosh MC, Mondal AC, Basu S, Banerjee S, Majumder J, et al. (2003) Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. Int Immunopharmacol 3: 1019-1026.
10. Haskó G, Szabó C, Németh ZH, Deitch EA, (2002) Dopamine suppresses IL-12 p40 production by lipopolysaccharide-stimulated macrophages via a β-adrenoceptor-mediated mechanism. J Neuroimmunol 122: 34-39.
11. Bach F, Grundmann U, Bauer M, Buchinger H, Soltész S, et al. (2002) Modulation of the inflammatory response to cardiopulmonary bypass by dopexamine and epidural anesthesia. Acta Anesthesiol Scand 46: 1227-1235.
12. Birnbaum J, Klotz E, Spies CD, Lorenz B, Stuebs P, et al. (2006) Effects of dopexamine on the intestinal microvascular blood flow and leukocyte activation in a sepsis model in rats. Crit Care 10: R117-124.
13. Zhu XH, Zellweger R, Wichmann MW, Ayala A, Chaudry IH, (2007) Effects of prolactin and metoclopramide on macrophage cytokine gene expression in late sepsis. Cytokine 9: 437-446.
14. Hoeger S, Gottmann U, Liu Z, Schnuelle P, Birck R, et al. (2007) Dopamine treatment in brain-dead rats mediates anti-inflammatory effects: the role of hemodynamic stabilization and D-receptor stimulation. Transpl Int 20: 790-799.
15. Hoeger S, Reisenbuechler A, Gottmann U, Doyon F, Braun C, et al. (2008) Donor dopamine treatment in brain dead rats is associated with an improvement in renal function early after transplantation and a reduction in renal inflammation. Transpl Int 21: 1072-1080.
16. Zhang MZ, Yao B, Wang S, Fan X, Wu G, et al. (2011) Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice. J Clin Invest 121: 2845-2854.
17. Yang S, Yao B, Zhou Y, Yin H, Zhang MZ, et al. (2012) Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury. Am J Physiol Renal Physiol 302: F742-F749.
18. Levite M, (2008) Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr Opin Pharmacol l8: 460-471.
19. Morikawa K, Oseko F, Morikawa S, (1994) Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro. Clin Exp Immunol 95: 514-518.
20. Besser MJ, Ganor Y, Levite M, (2005) Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human t-cells and triggers the selective secretion of either IL-10, TNFα or both. J Neuroimmunol 169: 161-171.
21. Laengle UW, Markstein R, Pralet D, Seewald W, Roman D, (2006) Effect of GLC756, a novel mixed dopamine D1 receptor antagonist and dopamine D2 receptor agonist, on TNF-α release in vitro from activated rat mast cells. Exp Eye Res 83: 1335-1339.
22. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, et al. (2002) Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 82: S12-22.
23. Woost PG, Kolb RJ, Finesilver M, Mackraj I, Imboden H, et al. (2006) Strategy for the development of a matched set of transport-competent, angiotensin receptor-deficient proximal tubule cell lines. In Vitro Cell Dev Biol Anim 42: 189-200.
24. Ferguson SM, Norton CS, Watson SJ, Akil H, Robinson TE, (2003) Amphetamine-evoked c-fos mRNA expression in the caudate-putamen: the effects of DA and NMDA receptor antagonists vary as a function of neuronal phenotype and environmental context. J Neurochem 86: 33-44.
25. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25: 402-408.
26. Yoneda M, Sanada H, Yatabe J, Midorikawa S, Hashimoto S, et al. (2005) Differential effects of angiotensin II type-1 receptor antisense oligonucleotides on renal function in spontaneously hypertensive rats. Hypertension 48: 58-65.
27. Bonecchi R, Galliera E, Borroni EM, Corsi M, Locati M, et al. (2009) Chemokines and chemokine receptors: an overview. Front Biosci 14: 540-551.
28. Romagnani P, Beltrame C, Annunziato F, Lasagni L, Luconi M, et al. (1999) Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. J Am Soc Nephrol 10: 2518-2526.
29. Zheng L, Sinniah R, I-Hong Hsu S, (2008) Pathogenic Role of NFkB activation in tubulointerstitial inflammatory lesions in human lupus nephritis. J Histochem Cytochem 56: 517-529.
30. Aggarwal BB, (2003) Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol 3: 745-756.
31. Patel NS, Chatterjee PK, Di Paola R, Mazzon E, Britti D, et al. (2005) Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther 312: 1170-1178.
32. Mosser DM, Zhang X, (2008) Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226: 205-218.
33. Sanz AB, Sanchez-Niño MD, Ramos AM, Moreno JA, Santamaria B, et al. (2010) NFkB in renal inflammation. J Am Soc Nephrol 21: 1254-1262.
34. Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, et al. (2009) Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 75: 936-944.
35. Donnahoo KK, Shames BD, Harken AH, Meldrum DR, (1999) Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 162: 196-203.
36. Shahid M, Francis J, Matrougui K, Majid DS, (2010) Involvement of tumor necrosis factor-α in natriuretic response to systemic infusion of nitric oxide synthase inhibitor in anesthetized mice. Am J Physiol Renal Physiol 299: F217-F224.
37. Dempsey PW, Doyle SE, He JQ, Cheng G, (2003) The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 14: 193-209.
38. Li Q, Verma IM, (2002) NFkB regulation in the immune system. Nat Rev Immunol 2: 725-734.
39. Covert MW, Leung TH, Gaston JE, Baltimore D, (2005) Achieving stability of lipopolycacharide-induced NFkB activation. Science 309: 1954-1857.
40. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, et al. (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327-336.
41. Yang M, Zhang H, Voyno-Yasenetskaya T, Ye RD, (2003) Requirement of Gβγ and c-Src in D2 dopamine receptor-mediated nuclear factor-κB activation. Mol Pharmacol 64: 447-455.
42. Takeuchi Y, Fukunaga K, (2003) Differential regulation of NF-κB, SRE and CRE by dopamine D1 and D2 receptors in transfected NG108-15 cells. J Neurochem 85: 729-739.
43. Lavender P, Cousins D, Lee T, (2000) Regulation of Th2 cytokine gene transcription. Chem Immunol 78: 16-29.
44. Zhu J, (2010) Transcriptional regulation of Th2 cell differentiation. Immunol Cell Biol 88: 244-249.
45. Tian N, Moore RS, Phillips WE, Lin L, Braddy S, et al. (2008) NADPH oxidase contributes to renal damage and dysfunction in Dahl salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol 295: R1858-R1865.
46. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, et al. (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12: 205-216.
47. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, et al. (1997) D2 dopamine receptor gene (DRD2) Taq1A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7: 479-484.
48. Pohjalainen T, Rinne JO, Någren K, Lehikoinen P, Anttila K, et al. (1998) The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 3: 256-260.
49. Jönsson EG, Nöthen MM, Grünhage F, Farde L, Nakashima Y, et al. (1999) Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4: 290-296.
50. Ritchie T, Noble EP, (2003) Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 28: 73-82.
51. Fang YJ, Thomas GN, Xu ZL, Fang JQ, Critchley JA, et al. (2005) An affected pedigree member analysis of linkage between the dopamine D2 receptor gene TaqI polymorphism and obesity and hypertension. Int J Cardiol 102: 111-116.
52. Rosmond R, Rankinen T, Chagnon M, Pérusse L, Chagnon YC, et al. (2001) Polymorphism in exon 6 of the dopamine D(2) receptor gene (DRD2) is associated with elevated blood pressure and personality disorders in men. J Hum Hypertens 15: 553-558.
53. Thomas GN, Critchley JA, Tomlinson B, Cockram CS, Chan JC, (2001) Relationships between the taqI polymorphism of the dopamine D2 receptor and blood pressure in hyperglycaemic and normoglycaemic Chinese subjects. Clin Endocrinol (Oxf) 55: 605-611.
54. Prasad P, Kumar KM, Ammini AC, Gupta A, Gupta R, et al. (2008) Association of dopaminergic pathway gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes. BMC Genet 9: 26.